BR112021018545A2 - Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente - Google Patents

Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente

Info

Publication number
BR112021018545A2
BR112021018545A2 BR112021018545A BR112021018545A BR112021018545A2 BR 112021018545 A2 BR112021018545 A2 BR 112021018545A2 BR 112021018545 A BR112021018545 A BR 112021018545A BR 112021018545 A BR112021018545 A BR 112021018545A BR 112021018545 A2 BR112021018545 A2 BR 112021018545A2
Authority
BR
Brazil
Prior art keywords
cancer
nqo1
bioactivatable
drug
combination
Prior art date
Application number
BR112021018545A
Other languages
English (en)
Portuguese (pt)
Inventor
David Boothman
Lingxiang Jiang
j hergenrother Paul
Xiaoguang Li
Xiumei Huang
Yang-Xin Fu
Original Assignee
Univ Indiana Res & Tech Corp
Univ Texas
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp, Univ Texas, Univ Illinois filed Critical Univ Indiana Res & Tech Corp
Publication of BR112021018545A2 publication Critical patent/BR112021018545A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021018545A 2019-03-18 2020-03-18 Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente BR112021018545A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
BR112021018545A2 true BR112021018545A2 (pt) 2021-12-14

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018545A BR112021018545A2 (pt) 2019-03-18 2020-03-18 Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente

Country Status (10)

Country Link
US (1) US20220160703A1 (https=)
EP (1) EP3942061A4 (https=)
JP (1) JP2022525476A (https=)
KR (1) KR20220004025A (https=)
CN (1) CN113905763A (https=)
AU (1) AU2020240035A1 (https=)
BR (1) BR112021018545A2 (https=)
CA (1) CA3130513A1 (https=)
MX (1) MX2021011301A (https=)
WO (1) WO2020190990A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2619331T (pt) * 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1
CA2909091C (en) * 2013-04-09 2021-11-02 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
SG11201808306PA (en) * 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
KR102922386B1 (ko) * 2017-07-21 2026-02-04 제넨테크, 인크. 암에 대한 치료 및 진단 방법

Also Published As

Publication number Publication date
CN113905763A (zh) 2022-01-07
EP3942061A1 (en) 2022-01-26
CA3130513A1 (en) 2020-09-24
JP2022525476A (ja) 2022-05-16
MX2021011301A (es) 2022-01-19
EP3942061A4 (en) 2022-12-14
WO2020190990A1 (en) 2020-09-24
AU2020240035A1 (en) 2021-10-07
US20220160703A1 (en) 2022-05-26
KR20220004025A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112016000898A2 (pt) Método para parada, proteção e preservação de órgão e redução de lesão de tecido
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
MX2016015346A (es) Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112015025662A2 (pt) terapia de combinação seletiva de tumor
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112018074755A2 (pt) composição líquida não oleosa, não aquosa, e, métodos para controle de pragas e para melhorar o crescimento das plantas.
AR086315A1 (es) Metodo y composicion para tratamiento de semillas
PE20200295A1 (es) Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas
ECSP10010716A (es) Combinaciones farmaceuticas.
Shahani et al. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?
BR112021018545A2 (pt) Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) ; INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) ; THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.